FREE Account Opening + No Clearing Fees
Loading...

Evoq Remedies IPO vs p e-analytics-ipo

Comparision between Evoq Remedies IPO and p e-analytics-ipo.

IPO Details

Evoq Remedies IPO is a SME Book Built Issue IPO proposed to list at BSE SME while p e-analytics-ipo is a SME Book Built Issue proposed to list at NSE SME.

  Evoq Remedies IPO p e-analytics-ipo
Logo Evoq Remedies IPO Logo p e-analytics-ipo Logo
Issue Category SME SME
Issue Type IPO IPO
Process Type Fixed Price Issue Book Built Issue
Listing At BSE SME NSE SME
Lead Managers Swastika Investmart Ltd Sarthi Capital Advisors Private Limited
Registrar Bigshare Services Pvt Ltd Bigshare Services Pvt Ltd
Market Maker
DRHP DRHP DRHP
RHP RHP RHP
Anchor Investor
IPO Allotment URL IPO Allotment URL IPO Allotment URL

Issue Size and Price

The total issue size of Evoq Remedies IPO is up to ₹9.72 Cr whereas the issue size of the p e-analytics-ipo is up to ₹31.60 Cr. The final issue price of Evoq Remedies IPO is ₹27.00 per share and of p e-analytics-ipo is ₹114.00 per share.

  Evoq Remedies IPO p e-analytics-ipo
Face Value ₹10 per share ₹10 per share
Issue Price (Lower) ₹111.00 per share
Issue Price (Upper) ₹114.00 per share
Issue Price (Final) ₹27.00 per share ₹114.00 per share
Discount (Retail)
Discount (Employee)
Market Lot Size 4000 shares 1200 shares
Fresh Issue Size 36,00,000 shares 14,52,000 shares
Fresh Issue Size (Amount) up to ₹9.72 Cr up to ₹16.55 Cr
OFS Issue Size 13,20,000 shares
OFS Issue Size (Amount) up to ₹15.05 Cr
Issue Size Total 36,00,000 shares 27,72,000 shares
Issue Size Total (Amount) up to ₹9.72 Cr up to ₹31.60 Cr

IPO Timetable

Evoq Remedies IPO opens on Mar 17, 2022, while p e-analytics-ipo opens on Mar 22, 2022. The closing date of Evoq Remedies IPO and p e-analytics-ipo is Mar 22, 2022, and Mar 25, 2022, respectively.

  Evoq Remedies IPO p e-analytics-ipo
Anchor Bid Date
Issue Open Mar 17, 2022 Mar 22, 2022
Issue Close Mar 22, 2022 Mar 25, 2022
Basis Of Allotment (Tentative) Mar 25, 2022 Mar 30, 2022
Initiation of Refunds (Tentative) Mar 28, 2022 Mar 31, 2022
Credit of Share (Tentative) Mar 29, 2022 Apr 01, 2022
Listing date (Tentative) Mar 30, 2022 Apr 04, 2022
Anchor Lockin End date 1 Apr 24, 2022 Apr 29, 2022
Anchor Lockin End date 2 Jun 23, 2022 Jun 28, 2022

Financials

Evoq Remedies IPO P/E ratio is 33.75, as compared to p e-analytics-ipo P/E ratio of 14.56.

  Evoq Remedies IPO p e-analytics-ipo
Financial
Summary of financial Information (Restated Consolidated)
Particulars For the year/period ended (Rs in Lakh)
  10-Feb-22 31-Mar-21 31-Mar-20 31-Mar-19
Total Assets 2660.58 804.63 565.22 214.78
Total Revenue 1056.58 1002.48 907.21 325
Profit After Tax 93.67 71.38 0.03 1.11
Summary of financial Information (Restated Consolidated)
Particulars For the year/period ended (Rs in Lakhs)
  30-Sep-21 31-Mar-21 31-Mar-20 31-Mar-19
Total Assets 3,678.60 3,193.65 2,950.95 2,745.66
Total Revenue 1,215.08 1,975.80 1,724.36 1,613.44
Profit After Tax 410.63 692.19 117.03 347.74
Promoter Shareholding (Pre-Issue) 99.99% 96.11%
Promoter Shareholding (Post-Issue) 73.53% 70.20%
P/E Ratio 33.75 14.56
Market Cap ₹36.72 Cr. ₹119.50 Cr.
ROE
ROCE
Debt/Equity
EPS
RoNW

Shares Offered

In the Evoq Remedies IPO retail investors (RII) are offered 17,10,000 shares while in p e-analytics-ipo retail investors are offered 17,10,000 shares. Qualified institutional buyers (QIB) are offered in Evoq Remedies IPO and 13,15,200 shares in p e-analytics-ipo.

  Evoq Remedies IPO p e-analytics-ipo
Anchor Investor Reserveration
Market Maker Reserveration 1,80,000 shares 1,39,200 shares
QIB 13,15,200 shares
NII 17,10,000 shares 3,96,000 shares
RII 17,10,000 shares 9,21,600 shares
Employee
Others
Total 34,20,000 shares 26,32,800 shares

Bids Received (Subscription)

Evoq Remedies IPO subscribed 1.67x in total, whereas p e-analytics-ipo subscribed 46.34x.

  Evoq Remedies IPO p e-analytics-ipo
QIB (times) 13.22x
NII (times) 0.30x 126.40x
Big NII (times)
Small NII (times)
RII (times) 3.03x 59.20x
Employee (times)
Other (times)
Total (times) 1.67x 46.34x

Comments

Add a public comment...